South Africa has requested the Serum Institute of India to take again the a million COVID-19 vaccine doses the corporate had despatched in early February, The Financial Occasions reported on Tuesday, a week after the nation mentioned it can placed on maintain use of AstraZeneca’s shot in its vaccination program.

Serum Institute of India, which is producing AstraZeneca’s shot, has emerged as a key vaccine provider. A million doses of the COVID-19 vaccine landed in South Africa final week and one other 500,000 have been as a consequence of arrive within the subsequent few weeks.

The corporate didn’t instantly reply to a Reuters request for remark.

South Africa’s well being minister has mentioned the federal government could promote doses of AstraZeneca’s vaccine, after the nation paused its rollout following a small scientific trial that confirmed it supplied minimal safety in opposition to gentle to reasonable sickness from the 501Y.V2 coronavirus variant dominant within the nation.

AstraZeneca has mentioned its vaccine appeared to supply solely restricted safety in opposition to gentle illness attributable to the South African variant, based mostly on knowledge from a research by South Africa’s College of the Witwatersrand and Oxford College.

The African nation, which is but to launch its COVID-19 vaccination program, has determined to begin vaccinating well being employees with Johnson & Johnson’s vaccine within the type of an “implementation research” with researchers.